Hit enter to search or ESC to close

Category: Investor Announcement

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Study demonstrates reduction of α-synuclein aggregation and preservation of neurons Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson’s Disease. MSA is ...

Appendix 4C – Q2 FY22 Quarterly Cash Flow Report

Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for a new class of compounds targeting Parkinson’s and Alzheimer’s diseases Active investor relations program in ...

WEBCAST LINK: H.C. Wainwright BIOCONNECT Virtual Conference

All stakeholders of Alterity Therapeutics, are invited to register to view the Company’s presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. Link to registration: https://journey.ct.events/view/21ae761a-b573-416e-b956-825d1f5a86b3 Alterity will begin its presentation on Monday 10/1/21 at 7:00 AM (Eastern Standard Time; 11:30pm AEST). A recorded copy of the webinar will be made available following the event.

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity. The composition of matter patent, entitled “Compounds for and Methods of Treating Diseases”, underwent ...

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The presentation will be accessible on the Alterity website under News on Monday, January ...

First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity’s Phase 2 clinical trial for ATH434 ...

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events: MST Financial Lifesciences & Biotech Fourm Wednesday, November 24th at 5:20 p.m. PST (U.S.) / Thursday, ...

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying video were delivered at the American Autonomic Society 32nd Annual Internation Symposium on the Autonomic Nervous System. The poster, entitled, Cardiovascular safety and pharmacokinetics of ATH434, ...
Senior male researcher carrying out scientific research

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

Colorectal impairment reversed in a preclinical model of Parkinson’s Disease   ATH434 presents a novel mechanism of action for the treatment of neurodegenerative diseases Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studies demonstrating ...